Literature DB >> 17108150

Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.

S M Alam1, J Fujimoto, I Jahan, E Sato, T Tamaya.   

Abstract

BACKGROUND: The ligand ephrinB2 and the corresponding receptor EphB4 contribute to tumor growth in various human tumors. This prompted us to study the expression and localization of ephrinB2 and EphB4 in uterine endometrial cancers to analyze the ephrinB2/EphB4 functions against clinical backgrounds.
MATERIALS AND METHODS: We carried out immunohistochemistry and real-time RT-PCR to determine the histoscores and messenger RNA (mRNA) levels of ephrinB2 and EphB4, respectively, in 68 uterine endometrial cancers and 16 normal endometrium tissue samples. Patient prognoses were analyzed with a 60-month survival rate.
RESULTS: The localization of ephrinB2 and EphB4 was dominantly in the cancer cells of uterine endometrial cancer of all cases given. EphrinB2 and EphB4 histoscores were highly correlated with ephrinB2 and EphB4 mRNA levels, respectively (r = 0.864 and r = 0.615, P < 0.01). Both the histoscores and mRNA levels of ephrinB2 and EphB4 significantly increased with clinical stages (I < II < III, P < 0.01), dedifferentiation (G(1) < G(2) < G(3), P < 0.01) and myometrial invasion (A &lt; B < C, P < 0.01 for ephrinB2 and P < 0.05 for EphB4) in uterine endometrial cancers. The 60-month survival rates of the 34 patients with high ephrinB2 and EphB4 expression were poor (59% and 62% respectively), while for the other 34 patients with low ephrinB2 and EphB4 expression, they were significantly higher (85% and 82%, respectively).
CONCLUSIONS: EphrinB2 and EphB4 were overexpressed during the tumor advancement as dedifferentiation and myometrial invasion. Therefore, ephrinB2/EphB4 might work on tumor advancement and may be recognized as a novel prognostic indicator for uterine endometrial cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108150     DOI: 10.1093/annonc/mdl414

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  18 in total

1.  Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.

Authors:  Benjamin D Ferguson; Maria S Tretiakova; Mark W Lingen; Parkash S Gill; Ravi Salgia
Journal:  Growth Factors       Date:  2014-11-13       Impact factor: 2.511

2.  Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.

Authors:  Yanyang Tu; Shiming He; Jianfang Fu; Gang Li; Ruxiang Xu; Hongliu Lu; Jianping Deng
Journal:  Clin Transl Oncol       Date:  2012-03       Impact factor: 3.405

3.  Molecular Targets for Improving Arteriovenous Fistula Maturation and Patency.

Authors:  Jolanta Gorecka; Arash Fereydooni; Luis Gonzalez; Shin Rong Lee; Shirley Liu; Shun Ono; Jianbiao Xu; Jia Liu; Ryosuke Taniguchi; Yutaka Matsubara; Xixiang Gao; Mingjie Gao; John Langford; Bogdan Yatsula; Alan Dardik
Journal:  Vasc Investig Ther       Date:  2019-10-09

4.  Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.

Authors:  Ayman Oweida; Shilpa Bhatia; Kellen Hirsch; Dylan Calame; Anastacia Griego; Steve Keysar; Todd Pitts; Jaspreet Sharma; Gail Eckhardt; Antonio Jimeno; Xiao Jing Wang; Gill Parkash; Joseph Califano; Sana D Karam
Journal:  Mol Carcinog       Date:  2016-11-01       Impact factor: 4.784

5.  Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro.

Authors:  Shikun He; S Ram Kumar; Peng Zhou; Valery Krasnoperov; Stephen J Ryan; Parkash S Gill; David R Hinton
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

6.  The phosphorylation of ephrin-B2 ligand promotes glioma cell migration and invasion.

Authors:  Mitsutoshi Nakada; Eric M Anderson; Tim Demuth; Satoko Nakada; Linsey B Reavie; Kelsey L Drake; Dominique B Hoelzinger; Michael E Berens
Journal:  Int J Cancer       Date:  2010-03-01       Impact factor: 7.396

7.  Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo.

Authors:  Karina Palomares; Frederic Vigant; Ben Van Handel; Olivier Pernet; Kelechi Chikere; Patrick Hong; Sean P Sherman; Michaela Patterson; Dong Sung An; William E Lowry; Hanna K A Mikkola; Kouki Morizono; April D Pyle; Benhur Lee
Journal:  J Virol       Date:  2012-11-28       Impact factor: 5.103

8.  Novel strategy for selection of monoclonal antibodies against highly conserved antigens: phage library panning against ephrin-B2 displayed on yeast.

Authors:  Xiaoling Gu; Yogindra Vedvyas; Xiaoyue Chen; Tanwi Kaushik; Chang-Il Hwang; Xuebo Hu; Alexander Y Nikitin; Moonsoo M Jin
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

9.  The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.

Authors:  Benjamin D Ferguson; Ren Liu; Cleo E Rolle; Yi-Hung Carol Tan; Valery Krasnoperov; Rajani Kanteti; Maria S Tretiakova; Gustavo M Cervantes; Rifat Hasina; Robyn D Hseu; A John Iafrate; Theodore Karrison; Mark K Ferguson; Aliya N Husain; Leonardo Faoro; Everett E Vokes; Parkash S Gill; Ravi Salgia
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

10.  Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.

Authors:  S M Alam; J Fujimoto; I Jahan; E Sato; T Tamaya
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.